TY - JOUR AU - Papageorgiou, N. AU - Sohrabi, C. AU - Prieto Merino, D. AU - Tyrlis, A. AU - Atieh, A.E. AU - Saberwal, B. AU - Lim, W.-Y. AU - Creta, A. AU - Khanji, M. AU - Rusinova, R. AU - Chooneea, B. AU - Khiani, R. AU - Wijesuriya, N. AU - Chow, A. AU - Butt, H. AU - Browne, S. AU - Joshi, N. AU - Kay, J. AU - Ahsan, S. AU - Providencia, R. KW - cardiovascular disease KW - COVID-19 KW - outcomes KW - Troponin T1 - High sensitivity troponin and COVID-19 outcomes LA - eng PY - 2022/// SP - 81 EP - 88 T2 - Acta Cardiologica SN - 0373-7934 VL - 77 IS - 1 PB - Taylor and Francis Ltd. AB - Background: Recent reports have demonstrated high troponin levels in patients affected with COVID-19. In the present study, we aimed to determine the association between admission and peak troponin levels and COVID-19 outcomes. Methods: This was an observational multi-ethnic multi-centre study in a UK cohort of 434 patients admitted and diagnosed COVID-19 positive, across six hospitals in London, UK during the second half of March 2020. Results: Myocardial injury, defined as positive troponin during admission was observed in 288 (66.4%) patients. Age (OR: 1.68 [1.49–1.88], p <.001), hypertension (OR: 1.81 [1.10–2.99], p =.020) and moderate chronic kidney disease (OR: 9.12 [95% CI: 4.24–19.64], p <.001) independently predicted myocardial injury. After adjustment, patients with positive peak troponin were more likely to need non-invasive and mechanical ventilation (OR: 2.40 [95% CI: 1.27–4.56], p =.007, and OR: 6.81 [95% CI: 3.40–13.62], p <.001, respectively) and urgent renal replacement therapy (OR: 4.14 [95% CI: 1.34–12.78], p =.013). With regards to events, and after adjustment, positive peak troponin levels were independently associated with acute kidney injury (OR: 6.76 [95% CI: 3.40–13.47], p <.001), venous thromboembolism (OR: 11.99 [95% CI: 3.20–44.88], p <.001), development of atrial fibrillation (OR: 10.66 [95% CI: 1.33–85.32], p =.026) and death during admission (OR: 2.40 [95% CI: 1.34–4.29], p =.003). Similar associations were observed for admission troponin. In addition, median length of stay in days was shorter for patients with negative troponin levels: 8 (5–13) negative, 14 (7–23) low-positive levels and 16 (10–23) high-positive (p <.001). Conclusions: Admission and peak troponin appear to be predictors for cardiovascular and non-cardiovascular events and outcomes in COVID-19 patients, and their utilisation may have an impact on patient management. DO - 10.1080/00015385.2021.1887586 UR - https://portalcientifico.uah.es/documentos/642b389fa1c8a315fd235b9c DP - Dialnet - Portal de la Investigación ER -